Nardo Christopher J. 4
4 · Dermata Therapeutics, Inc. · Filed Aug 17, 2021
Insider Transaction Report
Form 4
Nardo Christopher J.
Senior VP, CDO
Transactions
- Conversion
Common Stock
2021-08-17+2,439→ 2,439 total(indirect: By Trust) - Conversion
Series 1 Preferred Stock
2021-08-17−50,000→ 0 total(indirect: By Trust)→ Common Stock (2,439 underlying)
Holdings
- 25,121
Common Stock
Footnotes (2)
- [F1]The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date.
- [F2]Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.